Live
- Three held for stealing copper wire
- Gold rates in Delhi today surges, check the rates on 04 December, 2024
- Qatar maintains suspension of mediation efforts for Gaza ceasefire
- Gold rates in Vijayawada today surges, check the rates on 04 December, 2024
- US moves to phase out minimum-wage waiver for disabled workers
- Five killed in head-on collision between two vehicles in Rajasthan's Churu
- ISRO Scientists visit Tirumala seeks blessing for PSLV launch
- Gold rates in Hyderabad today surges, check the rates on 04 December, 2024
- Civic chief visits Jaipur Municipal Corporation
- Educational institutions should be made tobacco-free: DC
Dr. Reddy's Laboratories defends its right to launch Buprenorphine and Naloxone Sublingual Film in the U.S. Market
announced today that following the launch of its generic Buprenorphine and Naloxone Sublingual Film in the U.S. Market, the U.S. District Court for the District of New Jersey has received and reviewed an emergency application from the plaintiffs in the current patent litigation for a temporary restraining order and preliminary injunction against Dr. Reddy’s.
Hyderabad, India and Princeton, NJ, USA. June 16, 2018— Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that following the launch of its generic Buprenorphine and Naloxone Sublingual Film in the U.S. Market, the U.S. District Court for the District of New Jersey has received and reviewed an emergency application from the plaintiffs in the current patent litigation for a temporary restraining order and preliminary injunction against Dr. Reddy’s.
Pending a hearing and decision on the injunction application, the court has issued a temporary restraining order against Dr. Reddy’s with respect to further sales and commercialization of Buprenorphine and Naloxone Sublingual Film within the U.S. The court order does not include a prohibition on commercial manufacturing of the product. The plaintiffs will be required to post a bond or other security totaling $18 million (USD) to satisfy any losses or damages incurred by Dr. Reddy’s during the period of the temporary restraining order.
The court has scheduled an expedited hearing of the preliminary injunction for Thursday, June 28, and a ruling is expected soon thereafter. The proceeding only involves one patent, U.S. Patent No. 9,931,305. Dr. Reddy’s remains confident in its legal positions on this patent and believes it will prevail on the issues raised with respect to the application for injunction.
